ID   ADCY9_HUMAN             Reviewed;        1353 AA.
AC   O60503; A7E2V5; A7E2X2; D3DUD1; O60273; Q4ZHT9; Q4ZIR5; Q9BWT4;
AC   Q9UGP2;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   13-DEC-2002, sequence version 4.
DT   10-MAY-2017, entry version 154.
DE   RecName: Full=Adenylate cyclase type 9 {ECO:0000303|PubMed:9628827};
DE            EC=4.6.1.1 {ECO:0000269|PubMed:10987815, ECO:0000269|PubMed:12972952, ECO:0000269|PubMed:15879435, ECO:0000269|PubMed:9628827};
DE   AltName: Full=ATP pyrophosphate-lyase 9;
DE   AltName: Full=Adenylate cyclase type IX {ECO:0000303|PubMed:10987815};
DE            Short=ACIX {ECO:0000303|PubMed:10987815};
DE   AltName: Full=Adenylyl cyclase 9;
DE            Short=AC9 {ECO:0000303|PubMed:15879435};
GN   Name=ADCY9; Synonyms=KIAA0520;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, FUNCTION, ENZYME
RP   REGULATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=9628827; DOI=10.1006/geno.1998.5293;
RA   Hacker B.M., Tomlinson J.E., Wayman G.A., Sultana R., Chan G.,
RA   Villacres E., Disteche C., Storm D.R.;
RT   "Cloning, chromosomal mapping, and regulatory properties of the human
RT   type 9 adenylyl cyclase (ADCY9).";
RL   Genomics 50:97-104(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, AND VARIANT MET-772.
RX   PubMed=12972952; DOI=10.1097/00008571-200309000-00002;
RA   Small K.M., Brown K.M., Theiss C.T., Seman C.A., Weiss S.T.,
RA   Liggett S.B.;
RT   "An Ile to Met polymorphism in the catalytic domain of adenylyl
RT   cyclase type 9 confers reduced beta2-adrenergic receptor
RT   stimulation.";
RL   Pharmacogenetics 13:535-541(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, AND VARIANT MET-772.
RX   PubMed=15879435; DOI=10.1093/hmg/ddi175;
RA   Tantisira K.G., Small K.M., Litonjua A.A., Weiss S.T., Liggett S.B.;
RT   "Molecular properties and pharmacogenetics of a polymorphism of
RT   adenylyl cyclase type 9 in asthma: interaction between beta-agonist
RT   and corticosteroid pathways.";
RL   Hum. Mol. Genet. 14:1671-1677(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND VARIANT
RP   SER-1154.
RX   PubMed=10987815; DOI=10.1046/j.1471-4159.2000.0751358.x;
RA   Paterson J.M., Smith S.M., Simpson J., Grace O.C., Sosunov A.A.,
RA   Bell J.E., Antoni F.A.;
RT   "Characterisation of human adenylyl cyclase IX reveals inhibition by
RT   Ca(2+)/Calcineurin and differential mRNA plyadenylation.";
RL   J. Neurochem. 75:1358-1367(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Toyota T., Yamada K., Meerabux J., Hattori E., Saito K.,
RA   Yoshitsugu K., Shimizu H., Nankai M., Toru M., Detera-Wadleigh S.D.,
RA   Yoshikawa T.;
RT   "Mutation screening, case control study and transmission
RT   disequilibrium analysis of adenylate cyclase type 9 (ADCY9) gene in
RT   functional psychoses.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-1154.
RC   TISSUE=Brain;
RX   PubMed=9628581; DOI=10.1093/dnares/5.1.31;
RA   Nagase T., Ishikawa K., Miyajima N., Tanaka A., Kotani H., Nomura N.,
RA   Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. IX.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:31-39(1998).
RN   [7]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Ishikawa K.;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-1154.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1259, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1257 AND SER-1259, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-706, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Adenylyl cyclase that catalyzes the formation of the
CC       signaling molecule cAMP in response to activation of G protein-
CC       coupled receptors (PubMed:9628827, PubMed:12972952,
CC       PubMed:15879435, PubMed:10987815). Contributes to signaling
CC       cascades activated by CRH (corticotropin-releasing factor),
CC       corticosteroids and beta-adrenergic receptors (PubMed:9628827).
CC       {ECO:0000269|PubMed:10987815, ECO:0000269|PubMed:12972952,
CC       ECO:0000269|PubMed:15879435, ECO:0000269|PubMed:9628827}.
CC   -!- CATALYTIC ACTIVITY: ATP = 3',5'-cyclic AMP + diphosphate.
CC       {ECO:0000269|PubMed:10987815, ECO:0000269|PubMed:12972952,
CC       ECO:0000269|PubMed:15879435, ECO:0000269|PubMed:9628827}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P30803};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:P30803};
CC       Note=Binds 2 magnesium ions per subunit. Is also active with
CC       manganese (in vitro). {ECO:0000250|UniProtKB:P30803};
CC   -!- ENZYME REGULATION: Insensitive to calcium/calmodulin, forskolin
CC       and somatostatin. Stimulated by beta-adrenergic receptor
CC       activation (PubMed:9628827). Activity is down-regulated by
CC       calcium/calcineurin (PubMed:10987815).
CC       {ECO:0000269|PubMed:10987815, ECO:0000269|PubMed:9628827}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10987815,
CC       ECO:0000269|PubMed:9628827}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Detected in skeletal muscle, pancreas, lung,
CC       heart, kidney, liver, brain and placenta (PubMed:9628827,
CC       PubMed:10987815). Expressed in multiple cells of the lung, with
CC       expression highest in airway smooth muscle (PubMed:12972952).
CC       {ECO:0000269|PubMed:10987815, ECO:0000269|PubMed:12972952,
CC       ECO:0000269|PubMed:9628827}.
CC   -!- DOMAIN: The protein contains two modules with six transmembrane
CC       helices each; both are required for catalytic activity. Isolated
CC       N-terminal or C-terminal guanylate cyclase domains have no
CC       catalytic activity, but when they are brought together, enzyme
CC       activity is restored. The active site is at the interface of the
CC       two domains. Both contribute substrate-binding residues, but the
CC       catalytic metal ions are bound exclusively via the N-terminal
CC       guanylate cyclase domain. {ECO:0000250|UniProtKB:P26769}.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl
CC       cyclase family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC24201.1; Type=Frameshift; Positions=1252; Evidence={ECO:0000305};
CC       Sequence=BAA25446.3; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF036927; AAC24201.1; ALT_FRAME; mRNA.
DR   EMBL; DQ008441; AAY27880.1; -; mRNA.
DR   EMBL; DQ005545; AAY21237.1; -; mRNA.
DR   EMBL; AJ133123; CAB65084.1; -; mRNA.
DR   EMBL; AY028959; AAK29464.1; -; Genomic_DNA.
DR   EMBL; AY028949; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028950; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028951; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028952; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028953; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028954; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028955; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028956; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AY028957; AAK29464.1; JOINED; Genomic_DNA.
DR   EMBL; AB011092; BAA25446.3; ALT_INIT; mRNA.
DR   EMBL; CH471112; EAW85331.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85332.1; -; Genomic_DNA.
DR   EMBL; BC136657; AAI36658.1; -; mRNA.
DR   EMBL; BC136658; AAI36659.1; -; mRNA.
DR   EMBL; BC151207; AAI51208.1; -; mRNA.
DR   EMBL; BC151229; AAI51230.1; -; mRNA.
DR   CCDS; CCDS32382.1; -.
DR   RefSeq; NP_001107.2; NM_001116.3.
DR   UniGene; Hs.391860; -.
DR   UniGene; Hs.610484; -.
DR   ProteinModelPortal; O60503; -.
DR   SMR; O60503; -.
DR   BioGrid; 106628; 15.
DR   IntAct; O60503; 3.
DR   STRING; 9606.ENSP00000294016; -.
DR   ChEMBL; CHEMBL2655; -.
DR   iPTMnet; O60503; -.
DR   PhosphoSitePlus; O60503; -.
DR   BioMuta; ADCY9; -.
DR   EPD; O60503; -.
DR   MaxQB; O60503; -.
DR   PaxDb; O60503; -.
DR   PeptideAtlas; O60503; -.
DR   PRIDE; O60503; -.
DR   Ensembl; ENST00000294016; ENSP00000294016; ENSG00000162104.
DR   GeneID; 115; -.
DR   KEGG; hsa:115; -.
DR   UCSC; uc002cvx.4; human.
DR   CTD; 115; -.
DR   DisGeNET; 115; -.
DR   GeneCards; ADCY9; -.
DR   HGNC; HGNC:240; ADCY9.
DR   HPA; HPA041328; -.
DR   HPA; HPA044225; -.
DR   MIM; 603302; gene.
DR   neXtProt; NX_O60503; -.
DR   OpenTargets; ENSG00000162104; -.
DR   PharmGKB; PA30; -.
DR   eggNOG; KOG3618; Eukaryota.
DR   eggNOG; COG2114; LUCA.
DR   GeneTree; ENSGT00760000119042; -.
DR   HOVERGEN; HBG050459; -.
DR   InParanoid; O60503; -.
DR   KO; K08049; -.
DR   OMA; WHICLAV; -.
DR   OrthoDB; EOG091G0285; -.
DR   PhylomeDB; O60503; -.
DR   TreeFam; TF313845; -.
DR   Reactome; R-HSA-163359; Glucagon signaling in metabolic regulation.
DR   Reactome; R-HSA-163615; PKA activation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-170660; Adenylate cyclase activating pathway.
DR   Reactome; R-HSA-170670; Adenylate cyclase inhibitory pathway.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   SIGNOR; O60503; -.
DR   ChiTaRS; ADCY9; human.
DR   GeneWiki; ADCY9; -.
DR   GenomeRNAi; 115; -.
DR   PRO; PR:O60503; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000162104; -.
DR   CleanEx; HS_ADCY9; -.
DR   ExpressionAtlas; O60503; baseline and differential.
DR   Genevisible; O60503; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0008074; C:guanylate cyclase complex, soluble; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004016; F:adenylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004383; F:guanylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:Reactome.
DR   GO; GO:0034199; P:activation of protein kinase A activity; TAS:Reactome.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G-protein coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006171; P:cAMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 3.30.70.1230; -; 2.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   Pfam; PF00211; Guanylate_cyc; 2.
DR   SMART; SM00044; CYCc; 2.
DR   SUPFAM; SSF55073; SSF55073; 2.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 2.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; cAMP biosynthesis; Cell membrane; Complete proteome;
KW   Glycoprotein; Lyase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix.
FT   CHAIN         1   1353       Adenylate cyclase type 9.
FT                                /FTId=PRO_0000195708.
FT   TOPO_DOM      1    117       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    118    138       Helical. {ECO:0000255}.
FT   TOPO_DOM    139    141       Extracellular. {ECO:0000255}.
FT   TRANSMEM    142    162       Helical. {ECO:0000255}.
FT   TOPO_DOM    163    171       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    172    192       Helical. {ECO:0000255}.
FT   TOPO_DOM    193    215       Extracellular. {ECO:0000255}.
FT   TRANSMEM    216    235       Helical. {ECO:0000255}.
FT   TOPO_DOM    236    241       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    242    259       Helical. {ECO:0000255}.
FT   TOPO_DOM    260    280       Extracellular. {ECO:0000255}.
FT   TRANSMEM    281    301       Helical. {ECO:0000255}.
FT   TOPO_DOM    302    786       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    787    807       Helical. {ECO:0000255}.
FT   TOPO_DOM    808    818       Extracellular. {ECO:0000255}.
FT   TRANSMEM    819    839       Helical. {ECO:0000255}.
FT   TOPO_DOM    840    867       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    868    888       Helical. {ECO:0000255}.
FT   TOPO_DOM    889    891       Extracellular. {ECO:0000255}.
FT   TRANSMEM    892    912       Helical. {ECO:0000255}.
FT   TOPO_DOM    913    920       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    921    941       Helical. {ECO:0000255}.
FT   TOPO_DOM    942    975       Extracellular. {ECO:0000255}.
FT   TRANSMEM    976    996       Helical. {ECO:0000255}.
FT   TOPO_DOM    997   1353       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      394    521       Guanylate cyclase 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   DOMAIN     1058   1198       Guanylate cyclase 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   NP_BIND     399    404       ATP. {ECO:0000250|UniProtKB:P30803}.
FT   NP_BIND     441    443       ATP. {ECO:0000250|UniProtKB:P30803}.
FT   NP_BIND    1185   1187       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   NP_BIND    1192   1196       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   METAL       399    399       Magnesium 1; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   METAL       399    399       Magnesium 2; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   METAL       400    400       Magnesium 2; via carbonyl oxygen;
FT                                catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00099}.
FT   METAL       443    443       Magnesium 1; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   METAL       443    443       Magnesium 2; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   BINDING     487    487       ATP. {ECO:0000250|UniProtKB:P30803}.
FT   BINDING    1108   1108       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   BINDING    1232   1232       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   MOD_RES     610    610       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51830}.
FT   MOD_RES     688    688       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51830}.
FT   MOD_RES     691    691       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51830}.
FT   MOD_RES     706    706       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1257   1257       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1259   1259       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1295   1295       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51830}.
FT   MOD_RES    1307   1307       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   CARBOHYD    206    206       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    955    955       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    964    964       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT     772    772       I -> M (common polymorphism; found in
FT                                37.5% of the Asian population, in 30% of
FT                                the Caucasian population and in 16.3% of
FT                                the African-American population; reduced
FT                                adenylyl cyclase activity in response to
FT                                stimulation of the beta-adregnergic
FT                                receptor by Mn(2+) agonists isoproteronol
FT                                and NaF; increased albuterol-stimulated
FT                                adenylyl cyclase activity in the presence
FT                                of corticosteroid; dbSNP:rs2230739).
FT                                {ECO:0000269|PubMed:12972952,
FT                                ECO:0000269|PubMed:15879435}.
FT                                /FTId=VAR_023750.
FT   VARIANT    1154   1154       N -> S (in dbSNP:rs61731445).
FT                                {ECO:0000269|PubMed:10987815,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9628581}.
FT                                /FTId=VAR_070887.
FT   CONFLICT    493    493       G -> R (in Ref. 4; CAB65084).
FT                                {ECO:0000305}.
FT   CONFLICT    884    884       V -> A (in Ref. 4; CAB65084).
FT                                {ECO:0000305}.
FT   CONFLICT   1308   1308       P -> R (in Ref. 4; CAB65084).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1353 AA;  150701 MW;  4CBF051EA49B5B7B CRC64;
     MASPPHQQLL HHHSTEVSCD SSGDSNSVRV KINPKQLSSN SHPKHCKYSI SSSCSSSGDS
     GGVPRRVGGG GRLRRQKKLP QLFERASSRW WDPKFDSVNL EEACLERCFP QTQRRFRYAL
     FYIGFACLLW SIYFAVHMRS RLIVMVAPAL CFLLVCVGFF LFTFTKLYAR HYAWTSLALT
     LLVFALTLAA QFQVLTPVSG RGDSSNLTAT ARPTDTCLSQ VGSFSMCIEV LFLLYTVMHL
     PLYLSLCLGV AYSVLFETFG YHFRDEACFP SPGAGALHWE LLSRGLLHGC IHAIGVHLFV
     MSQVRSRSTF LKVGQSIMHG KDLEVEKALK ERMIHSVMPR IIADDLMKQG DEESENSVKR
     HATSSPKNRK KKSSIQKAPI AFRPFKMQQI EEVSILFADI VGFTKMSANK SAHALVGLLN
     DLFGRFDRLC EETKCEKIST LGDCYYCVAG CPEPRADHAY CCIEMGLGMI KAIEQFCQEK
     KEMVNMRVGV HTGTVLCGIL GMRRFKFDVW SNDVNLANLM EQLGVAGKVH ISEATAKYLD
     DRYEMEDGKV IERLGQSVVA DQLKGLKTYL ISGQRAKESR CSCAEALLSG FEVIDGSQVS
     SGPRGQGTAS SGNVSDLAQT VKTFDNLKTC PSCGITFAPK SEAGAEGGAP QNGCQDEHKN
     STKASGGPNP KTQNGLLSPP QEEKLTNSQT SLCEILQEKG RWAGVSLDQS ALLPLRFKNI
     REKTDAHFVD VIKEDSLMKD YFFKPPINQF SLNFLDQELE RSYRTSYQEE VIKNSPVKTF
     ASPTFSSLLD VFLSTTVFLT LSTTCFLKYE AATVPPPPAA LAVFSAALLL EVLSLAVSIR
     MVFFLEDVMA CTKRLLEWIA GWLPRHCIGA ILVSLPALAV YSHVTSEYET NIHFPVFTGS
     AALIAVVHYC NFCQLSSWMR SSLATVVGAG PLLLLYVSLC PDSSVLTSPL DAVQNFSSER
     NPCNSSVPRD LRRPASLIGQ EVVLVFFLLL LLVWFLNREF EVSYRLHYHG DVEADLHRTK
     IQSMRDQADW LLRNIIPYHV AEQLKVSQTY SKNHDSGGVI FASIVNFSEF YEENYEGGKE
     CYRVLNELIG DFDELLSKPD YSSIEKIKTI GATYMAASGL NTAQAQDGSH PQEHLQILFE
     FAKEMMRVVD DFNNNMLWFN FKLRVGFNHG PLTAGVIGTT KLLYDIWGDT VNIASRMDTT
     GVECRIQVSE ESYRVLSKMG YDFDYRGTVN VKGKGQMKTY LYPKCTDHRV IPQHQLSISP
     DIRVQVDGSI GRSPTDEIAN LVPSVQYVDK TSLGSDSSTQ AKDAHLSPKR PWKEPVKAEE
     RGRFGKAIEK DDCDETGIEE ANELTKLNVS KSV
//
